These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21416994)

  • 1. [Phosphodiesterase regulation of cardiovascular functions].
    Li L; He Q; Gao YS
    Sheng Li Ke Xue Jin Zhan; 2010 Apr; 41(2):100-6. PubMed ID: 21416994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
    Bobin P; Belacel-Ouari M; Bedioune I; Zhang L; Leroy J; Leblais V; Fischmeister R; Vandecasteele G
    Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase inhibitors for the treatment of erectile dysfunction.
    Küthe A; Montorsi F; Andersson KE; Stief CG
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1489-95. PubMed ID: 12431025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic nucleotide phosphodiesterases.
    Essayan DM
    J Allergy Clin Immunol; 2001 Nov; 108(5):671-80. PubMed ID: 11692087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.
    Lugnier C
    Pharmacol Ther; 2006 Mar; 109(3):366-98. PubMed ID: 16102838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase genes and antidepressant treatment response: a review.
    Esposito K; Reierson GW; Luo HR; Wu GS; Licinio J; Wong ML
    Ann Med; 2009; 41(3):177-85. PubMed ID: 18932104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders.
    Xu Y; Zhang HT; O'Donnell JM
    Handb Exp Pharmacol; 2011; (204):447-85. PubMed ID: 21695652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors.
    Willette RN; Shiloh AO; Sauermelch CF; Sulpizio A; Michell MP; Cieslinski LB; Torphy TJ; Ohlstein EH
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):210-9. PubMed ID: 9040501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K; Kass DA
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():455-479. PubMed ID: 27732797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS.
    Andersson KE; Uckert S; Stief C; Hedlund P
    Neurourol Urodyn; 2007 Oct; 26(6 Suppl):928-33. PubMed ID: 17806124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic nucleotide phosphodiesterases and vascular smooth muscle.
    Polson JB; Strada SJ
    Annu Rev Pharmacol Toxicol; 1996; 36():403-27. PubMed ID: 8725396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular implications in the use of PDE5 inhibitor therapy.
    Maurice DH
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S20-3. PubMed ID: 15224131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
    Sung BJ; Hwang KY; Jeon YH; Lee JI; Heo YS; Kim JH; Moon J; Yoon JM; Hyun YL; Kim E; Eum SJ; Park SY; Lee JO; Lee TG; Ro S; Cho JM
    Nature; 2003 Sep; 425(6953):98-102. PubMed ID: 12955149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overview of PDEs and their regulation.
    Omori K; Kotera J
    Circ Res; 2007 Feb; 100(3):309-27. PubMed ID: 17307970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cyclic nucleotide phosphodiesterase IV expression, activity and targeting in cells of cardiovascular system].
    Yan J; Zhu HB
    Yao Xue Xue Bao; 2007 Jun; 42(6):571-5. PubMed ID: 17702390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity.
    Gupta R; Kumar G; Kumar RS
    Methods Find Exp Clin Pharmacol; 2005 Mar; 27(2):101-18. PubMed ID: 15834463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.